A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
ConditionTetanus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorZhuhai Trinomab Pharmaceutical Co., Ltd.
About this trial
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Eligibility criteria
Qualifiers
1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury;
2. Provided signed informed consent by themselves or their legal representatives.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Siltartoxatug Injection (Brand name: Sintetol®)
Treatment groups
10,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov